share_log

4: Statement of changes in beneficial ownership of securities-Officer Claiborne Cary J

4: Statement of changes in beneficial ownership of securities-Officer Claiborne Cary J

4:持股變動聲明-高管 Claiborne Cary J
美股SEC公告 ·  2024/12/06 06:49

Moomoo AI 已提取核心訊息

Claiborne Cary J, CEO of Adial Pharmaceuticals, reported no transactions involving non-derivative securities as of 12/05/2024. The announcement indicates that there were no changes in his stock holdings during this period.This report is significant for investors monitoring insider activities, as it confirms the absence of stock sales or purchases by the CEO. Such information can be crucial for assessing insider confidence in the company's future performance.Investors should note that the lack of transactions does not imply any specific outlook on the company's stock performance. It merely reflects the current status of the CEO's holdings as of the reported date.
Claiborne Cary J, CEO of Adial Pharmaceuticals, reported no transactions involving non-derivative securities as of 12/05/2024. The announcement indicates that there were no changes in his stock holdings during this period.This report is significant for investors monitoring insider activities, as it confirms the absence of stock sales or purchases by the CEO. Such information can be crucial for assessing insider confidence in the company's future performance.Investors should note that the lack of transactions does not imply any specific outlook on the company's stock performance. It merely reflects the current status of the CEO's holdings as of the reported date.
截至2024年5月12日,Adial Pharmicals首席執行官克萊伯恩·卡里·J沒有報告任何涉及非衍生證券的交易。該公告表明,在此期間,他的股票持有量沒有變化。該報告對監督內幕活動的投資者具有重要意義,因爲它證實了首席執行官沒有出售或購買股票。這些信息對於評估內部人士對公司未來業績的信心可能至關重要。投資者應注意,缺乏交易並不意味着對公司股票表現有任何具體展望。它僅反映了首席執行官截至報告日的持股現狀。
截至2024年5月12日,Adial Pharmicals首席執行官克萊伯恩·卡里·J沒有報告任何涉及非衍生證券的交易。該公告表明,在此期間,他的股票持有量沒有變化。該報告對監督內幕活動的投資者具有重要意義,因爲它證實了首席執行官沒有出售或購買股票。這些信息對於評估內部人士對公司未來業績的信心可能至關重要。投資者應注意,缺乏交易並不意味着對公司股票表現有任何具體展望。它僅反映了首席執行官截至報告日的持股現狀。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息